Trials / Completed
CompletedNCT04755894
HDDO-1756 Bio Equivalence Study
A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of HDDO-1756 or Loose Combination of HDDO-17561/HDDO-17562 in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Hyundai Pharmaceutical Co., LTD. · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
For healthy adult volunteers, safety and pharmacokinetic properties are compared between the two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562 combined administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDDO-1756 | single dose |
| DRUG | HDDO-17561/HDDO-17562 | single dose |
Timeline
- Start date
- 2020-06-12
- Primary completion
- 2020-06-19
- Completion
- 2020-07-27
- First posted
- 2021-02-16
- Last updated
- 2021-02-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04755894. Inclusion in this directory is not an endorsement.